This site is intended only for healthcare professionals resident in the Republic of Ireland




Sign in or RegisterLog out Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up



DosingMechanism of ActionSafety & TolerabilityEfficacy & Clinical DataSupport & ResourcesMaterialsVideosPrescribing Information
Safety and tolerabilityINLYTA® has a well-characterised safety and tolerability profile1–5 

Over 10 years, clinicians’ experience of INLYTA® has demonstrated the safety and tolerability profile of INLYTA® observed in clinical trials.1–5 

  • Only 4% of patients discontinued treatment with INLYTA® due to AEs in a Phase III clinical trial with INLYTA® monotherapy2
Common treatment emergent all-causality AEs in the AXIS study2 
Scroll left to view table

The short half-life of INLYTA® ensures that it is cleared more quickly following dose interruptions/discontinuations:1,2 

INLYTA® (n=359) Sorafenib (n=355)
All grades (%)  ≥ Grade 3 (%) All grades (%) ≥ Grade 3 (%)
Diarrhoea 55 11 53 7
Hypertension  40 16 29 11
Fatigue 39 11 32 5
Decreased appetite 34 5 29 4
Nausea 32 3 22 1
Dysphonia 31 0 14 0
Hand–foot syndrome 27  5 51  16
Weight decreased 25  2 21 1
Vomiting 24 3 17 1
Asthenia 21 5 14 3
Constipation 20 1 20 1
Rash 13 <1 32 4
Alopecia 4 0 32 0
Hypothyroidism 19 <1 8 0
Cough 15 1 17 1
Mucosal inflammation 15 1 12 1
Arthralgia 15 1 11 1
Stomatitis 15 1 12 <1
Data are n (%).Adapted from Rini BI, et al. 2011. 

For some patients, taking a short break (e.g. 1–2 days) before restarting INLYTA® may help AEs to resolve quickly.1,6

AE, adverse event.
ReferencesINLYTA® Summary of Product Characteristics.Rini BI, et al. Lancet 2011;378:1931–1939.Melichar B, et al. Efficacy and tolerability of axitinib in metastatic renal cell carcinoma (mRCC): comparison of Czech clinical registry and AXIS trial data. ECC. 25–29 September 2015. Vienna, Austria. Poster: 2615.Matias M, et al. Eur J Cancer 2017;79:185–192.Rossetti S, et al. Activity of second line axitinib in metastatic renal cell carcinoma (mRCC) patients treated with sunitinib: results from SAX Italian real world trial. ASCO. 2–6 June 2017. Chicago, USA. Abstract: e16054.Larkin J, et al. Am J Clin Oncol 2014;37:397–403.
Resources Explore Loading

Legal Category: S1A
Further information is available upon request

PP-INL-IRL-0128 December 2022

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.


Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.